Research news // 5th December 2019
The 61st American Society of Hematology Annual Meeting (ASH) will be taking place on 7-10 December in Orlando, Florida. Our Director of Research Sarah McDonald and Director of Healthcare Advocacy Services Ira Laketic-Ljubojevic will be attending to see the progress from Myeloma UK funded research and report back on the latest myeloma research.
Results from research part-funded by Myeloma UK, the MUK nine and MUK seven clinical trials, will be presented at the meeting.
Preliminary results from MUK nine will be presented by Martin Kaiser from The Institute of Cancer Research, London. MUK nine is the first UK-wide trial using genetic screening to identify high-risk myeloma patients so they can receive more intensive treatment currently not available through the NHS. The trial has finished recruitment ahead of schedule and has demonstrated that multi-centre trials using genetic screening to group patients to determine treatment are feasible.
James Croft from the Royal Marsden Hospital will present results from MUK seven. The results will demonstrate how genetic biomarkers can also be used to define risk status and predict the treatment outcomes in relapsed/refractory myeloma patients.
Some of the other exciting topics on the meeting programme to include:
- Early results from trials exploring the use of dual-targeted CAR-T therapies designed to improve the efficacy of CAR-T therapies in myeloma.
- Results from clinical trials evaluating new drugs types including belantumab malfodotin, venetoclax and selinexor which work in different ways to treat myeloma and offer multi-relapsed patients new treatment options.
- Trials looking and new treatment approaches for at risk patient groups including transplant-ineligible and high-risk myeloma patients.
ASH is one of the biggest haematology conferences in the world with more than 25,000 attendees. Attendees will come from around the world to learn about the latest research covering more than 5,000 topics. These topics will include studies on why myeloma happens, why it differs between individuals and how we best treat it.